Notice of 2009 Half Year Results

8 July 2009

Vernalis plc (LSE: VER) today announces that it will be releasing its interim results for the six months ended 30 June 2009 on Thursday, 6th August.


An analyst briefing will be held at 9.00 am on 6th August at the offices of Brunswick Group, 16 Lincoln’s Inn Fields, London, WC2A 3ED.  Please advise Valerie Mugridge at Brunswick if you plan to attend on +44 (0) 207 396 5325.


-- ends --


Vernalis Contacts

Ian Garland, Chief Executive Officer                                       +44 (0) 118 977 3133
David Mackney, Chief Financial Officer

Brunswick Group

Jon Coles                                                                               +44 (0) 20 7404 5959
Justine McIlroy



Notes to Editors


About Vernalis

Vernalis is a development stage pharmaceutical company with significant expertise both in de novo fragment and structure-based drug discovery and pre-clinical and clinical development.  The Group has six development stage product candidates (two of which are partnered), two programmes in pre-clinical (one with a partner), one in late research as well as other competitive research programmes. Our collaborations with leading, global pharmaceutical companies include Biogen Idec, Novartis, Servier, Chiesi, Menarini and Endo.



For further information about Vernalis, please visit


Vernalis Forward-Looking Statement


This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Frova® and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.